The HER2 tri-specific antibody illustrated multiple anti-cancer effects such as T-cell stimulation, and activation of CD8 cytolytic functions, furthermore, they highlighted the importance of CD4-mediated tumor regression in humanized mouse models through the induction of breast cancer cell cycle arrest [143]. This evidence concerns the gene ERBB2 and breast carcinoma.